Letrozol Bluefish

Letrozole, the active ingredient in Letrozol Bluefish, is an aromatase inhibitor presented as a tablet for oral use. It treats hormone receptor‑positive breast cancer in postmenopausal women by lowering estrogen levels that can stimulate tumor growth. The medication is manufactured according to EU pharmaceutical standards and undergoes rigorous quality testing before distribution.

GNH USA supplies Letrozol Bluefish as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide, ensuring reliable global access to this essential cancer therapy.

Letrozole is employed in endocrine therapy targeting hormone‑dependent breast cancer pathways.

Hormone receptor‑positive breast cancer in postmenopausal women: reduces estrogen production to slow tumor progression. Adjuvant treatment of early‑stage breast cancer: helps prevent disease recurrence after surgery. Metastatic breast cancer in postmenopausal patients: provides disease control and prolongs survival.

Letrozole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aches in joints or muscles. - Fatigue: persistent tiredness. - Nausea: upset stomach and urge to vomit.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated liver enzymes. - Bone fractures: increased risk of osteoporosis‑related breaks. - Allergic reactions: rash, swelling, or anaphylaxis.

When prescribing Letrozol Bluefish, clinicians should observe several safety measures.

- Pregnancy contraindication: avoid use in pregnant women (Category X). - Postmenopausal status verification: confirm patient is postmenopausal before initiating therapy. - Bone health monitoring: assess bone mineral density periodically. - Liver function assessment: evaluate hepatic enzymes before and during treatment. - Cardiovascular risk evaluation: monitor blood pressure and lipid profile. - Store at room temperature: keep below 25 °C in original packaging, protect from moisture.

Letrozole can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce letrozole efficacy. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels and toxicity. - Estrogen‑containing hormone therapy: antagonizes letrozole’s estrogen‑lowering effect.

Moderate Interactions (Monitor Closely): - Warfarin: letrozole may enhance anticoagulant effect; monitor INR. - SSRIs (e.g., fluoxetine): potential for altered metabolism; observe for side effects. - Statins: possible increased risk of muscle toxicity; assess patient tolerance.